Stay updated on Satralizumab in Thyroid Eye Disease Clinical Trial
Sign up to get notified when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.

Latest updates to the Satralizumab in Thyroid Eye Disease Clinical Trial page
- Check3 days agoChange DetectedThe page now displays Revision: v3.5.2, replacing Revision: v3.5.0. This appears to be an internal version update with no visible changes to study information.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange Detected- Italy location entry updated from Napoli, Campania, Italy, 80131 to Naples, Campania, Italy, 80131.SummaryDifference0.0%

- Check32 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check67 days agoChange DetectedAdministrative changes: addition of revision v3.4.2 and removal of prior notices (including the lapse funding notice and revision v3.4.1); these updates do not affect study details, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check74 days agoChange DetectedA site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status has been added, including a link to cc.nih.gov and opm.gov. Revision metadata now shows Revision: v3.4.1 with dates 2026-02-03, 2026-01-30, and 2026-01, replacing Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Satralizumab in Thyroid Eye Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.